

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-61 (Cancelled).

62 (Currently Amended). A method ~~for the treatment of~~
~~a disease or disorder of the mucosa, the method comprising~~
administering to the gastrointestinal (GI) mucosa of a subject
~~in need of such treatment~~having a disease or disorder associated
with inflammation of the GI mucosa, in a manner and amount
effective to achieve topical treatment of said GI mucosa, a
medicament comprising negatively charged lipid assemblies loaded
with an active ingredient effective for the topical treatment of
said GI mucosa, where the active ingredient is not covalently
bound with the lipid assemblies.

63 (Cancelled)

64 (Previously Presented). A method according to
Claim 62, wherein the lipid assemblies are liposomes.

65 (Currently Amended). The method of Claim ~~63~~62,
wherein said GI mucosa is selected from the group consisting of

intestinal mucosa, small bowel mucosa, large bowel mucosa ~~or~~ and
the mucosa in the rectum.

66 (Cancelled).

67 (Currently Amended). The method of Claim 62,
wherein said lipid assemblies comprise one or more anionic
~~lipids~~ lipid selected from the group consisting of 1,2-
distearoyl-*sn*-glycero-3-[phospho-*rac*-(1-glycerol)] (DSPG), and
hydrogenated soy phosphoglycerol.

68 (Cancelled).

69 (Currently Amended). A method according to Claim
~~68, 62~~ wherein the disease or disorder is selected from the group
consisting of ulcerative colitis, Crohn's disease, gastric
ulceration, duodenal ulceration, ileitis, colitis, ileocolitis,
ulcerative proctitis, ~~gastroenteritis~~ gastroenteritis,
diverticulitis, diverticulosis, reflux, ulcer, gastritis,
dyspepsia, nausea, and abrasion to gastrointestinal tract.

70 (Currently Amended). The method of Claim ~~68, 62~~,
wherein said ~~disease or disorder is associated with~~
~~inflammation, and said medicament comprises an active ingredient~~
is an agent effective in inhibiting inflammatory responses.

71 (Currently Amended). A method according to Claim
~~70, 67~~, wherein the active agent is selected from ~~the group~~
consisting of steroids, salicylates, COX-2 inhibitors, anti-TNF α

drugs, antibiotics, ~~immunosuppressors~~immunosuppressors,
immunomodulators and antioxidants.

72 (Currently Amended). A method according to Claim ~~71~~67, wherein the active agent is selected from the group consisting of Prednisone, Prednisolone, methylprednisolone, methylprednisolone succinate, Budesonide, derivatives of 5-aminosalicylic acid (5ASA), ~~Sulfsalazine~~—, Mesalamine ~~(5ASA)~~, Olsalazine, Balsalazide, Metronidazole, Ciprofloxin, Probiotics, ~~9. Cyclosporin A~~, Azathioprine, Methotrexate and 6-Mercaptopurine.

73 (Currently Amended). The method of Claim ~~68~~62, wherein said ~~disease or disorder is associated with oxidative stress, and said medicament comprises as an active ingredient~~ one or more anti-oxidants.

74 (Currently Amended). The method of claim ~~73~~70 wherein the active agent is selected from the group consisting of ~~tocopherol, free radicals scavengers, SOD and SOD mimics, and catalase or therapeutic reducing agents.~~

75 (Currently Amended). The method of Claim ~~68~~62, wherein said disease or disorder is selected from the group consisting of ulcerative colitis, Crohn's disease, irritable bowel syndrome, colon carcinoma and familial adenomatous polyposis.

76-79 (Cancelled).

Appln. No. 10/578,090
Amendment dated November 26, 2010
Reply to Office Action of July 26, 2010

80 (New). The method of Claim 74, wherein said active ingredient is selected from the group consisting of tocopherol, superoxide dismutase (SOD) and SOD mimics.